PAPA · As filed with the SEC
Papa Medical income statement, by quarter
The statement as Papa Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income · USD
| USD | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 |
|---|---|---|
| Revenues | 7,368,220 | 14,711,421 |
| Cost of revenues | (5,948,565) | (11,062,007) |
| Gross profit | 1,419,655 | 3,649,414 |
| Operating expenses: | ||
| Selling and marketing | (1,625,511) | (1,694,837) |
| General and administrative | (749,573) | (654,567) |
| Research and development | (329,505) | (329,096) |
| Total operating expenses | (2,704,589) | (2,678,500) |
| Operating income | (1,284,934) | 970,914 |
| Interest income, net | — | 27,176 |
| Interest income, net | 54 | — |
| Other loss, net | 987 | (57,442) |
| Income before income taxes | (1,283,893) | 940,648 |
| Income tax credit/(expense) | 463,970 | (319,425) |
| Net income attributable to the Company’s shareholders | (819,923) | 621,223 |
| Basic and diluted income per share | ||
| Net income per share - Basic | (0.04) | 0.03 |
| Net income per share - Diluted | (0.04) | 0.03 |
| Weighted average shares used in calculating net income per share | ||
| Weighted average shares used in calculating net income per share - Basic | 20,000,000 | 20,000,000 |
| Weighted average shares used in calculating net income per share - Diluted | 20,000,000 | 20,000,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.